BAUSCH HEALTH COS INC (BHC.CA) Stock Fundamental Analysis
Canada - TSX:BHC - CA0717341071 - Common Stock
9.53 CAD
-0.07 (-0.73%)
Overall BHC gets a fundamental rating of 4 out of 10. We evaluated BHC against 31 industry peers in the Pharmaceuticals industry. BHC has a medium profitability rating, but doesn't score so well on its financial health evaluation. BHC is valued quite cheap, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year BHC was profitable.
In the past year BHC had a positive cash flow from operations.
BHC had negative earnings in each of the past 5 years.
Of the past 5 years BHC 4 years had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 0.36%, BHC is in the better half of the industry, outperforming 67.74% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 6.09%, BHC belongs to the top of the industry, outperforming 83.87% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for BHC is below the industry average of 7.71%.
The 3 year average ROIC (5.45%) for BHC is below the current ROIC(6.09%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.36% | ||
| ROE | N/A | ||
| ROIC | 6.09% |
ROA(3y)-1.07%
ROA(5y)-1.65%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.45%
ROIC(5y)4.93%
1.3 Margins
BHC's Profit Margin of 0.99% is fine compared to the rest of the industry. BHC outperforms 74.19% of its industry peers.
BHC has a better Operating Margin (19.13%) than 87.10% of its industry peers.
In the last couple of years the Operating Margin of BHC has grown nicely.
With an excellent Gross Margin value of 70.70%, BHC belongs to the best of the industry, outperforming 90.32% of the companies in the same industry.
In the last couple of years the Gross Margin of BHC has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.13% | ||
| PM (TTM) | 0.99% | ||
| GM | 70.7% |
OM growth 3Y1.02%
OM growth 5Y4.43%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.24%
GM growth 5Y-0.44%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BHC is destroying value.
BHC has more shares outstanding than it did 1 year ago.
BHC has more shares outstanding than it did 5 years ago.
BHC has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 0.21, we must say that BHC is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.21, BHC is in the better half of the industry, outperforming 61.29% of the companies in the same industry.
BHC has a debt to FCF ratio of 19.69. This is a negative value and a sign of low solvency as BHC would need 19.69 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 19.69, BHC is in the better half of the industry, outperforming 64.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 19.69 | ||
| Altman-Z | 0.21 |
ROIC/WACC0.9
WACC6.77%
2.3 Liquidity
A Current Ratio of 1.31 indicates that BHC should not have too much problems paying its short term obligations.
BHC's Current ratio of 1.31 is on the low side compared to the rest of the industry. BHC is outperformed by 70.97% of its industry peers.
BHC has a Quick Ratio of 1.31. This is a bad value and indicates that BHC is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.98, BHC is not doing good in the industry: 61.29% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.31 | ||
| Quick Ratio | 0.98 |
3. Growth
3.1 Past
BHC shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.33%.
The Earnings Per Share has been decreasing by -2.91% on average over the past years.
Looking at the last year, BHC shows a quite strong growth in Revenue. The Revenue has grown by 9.91% in the last year.
Measured over the past years, BHC shows a small growth in Revenue. The Revenue has been growing by 2.28% on average per year.
EPS 1Y (TTM)1.33%
EPS 3Y-5.37%
EPS 5Y-2.91%
EPS Q2Q%2.65%
Revenue 1Y (TTM)9.91%
Revenue growth 3Y4.5%
Revenue growth 5Y2.28%
Sales Q2Q%6.81%
3.2 Future
BHC is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -0.15% yearly.
BHC is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.19% yearly.
EPS Next Y5.02%
EPS Next 2Y7.99%
EPS Next 3Y11.04%
EPS Next 5Y-0.15%
Revenue Next Year5.61%
Revenue Next 2Y4.68%
Revenue Next 3Y3.21%
Revenue Next 5Y-0.19%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
BHC is valuated cheaply with a Price/Earnings ratio of 1.77.
Based on the Price/Earnings ratio, BHC is valued cheaper than 100.00% of the companies in the same industry.
BHC is valuated cheaply when we compare the Price/Earnings ratio to 26.03, which is the current average of the S&P500 Index.
BHC is valuated cheaply with a Price/Forward Earnings ratio of 1.54.
100.00% of the companies in the same industry are more expensive than BHC, based on the Price/Forward Earnings ratio.
BHC is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.27, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.77 | ||
| Fwd PE | 1.54 |
4.2 Price Multiples
BHC's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BHC is cheaper than 90.32% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BHC indicates a rather cheap valuation: BHC is cheaper than 100.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 2.27 | ||
| EV/EBITDA | 7.2 |
4.3 Compensation for Growth
BHC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of BHC may justify a higher PE ratio.
PEG (NY)0.35
PEG (5Y)N/A
EPS Next 2Y7.99%
EPS Next 3Y11.04%
5. Dividend
5.1 Amount
No dividends for BHC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:BHC (11/4/2025, 7:00:00 PM)
9.53
-0.07 (-0.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners47.96%
Inst Owner ChangeN/A
Ins Owners10.81%
Ins Owner ChangeN/A
Market Cap3.52B
Revenue(TTM)9.63B
Net Income(TTM)98.00M
Analysts48.89
Price Target10.2 (7.03%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-16.1%
Min EPS beat(2)-25.13%
Max EPS beat(2)-7.07%
EPS beat(4)1
Avg EPS beat(4)-7.65%
Min EPS beat(4)-25.13%
Max EPS beat(4)5.95%
EPS beat(8)4
Avg EPS beat(8)-2.65%
EPS beat(12)6
Avg EPS beat(12)-3.66%
EPS beat(16)8
Avg EPS beat(16)-5.48%
Revenue beat(2)1
Avg Revenue beat(2)-0.61%
Min Revenue beat(2)-1.57%
Max Revenue beat(2)0.36%
Revenue beat(4)3
Avg Revenue beat(4)0.46%
Min Revenue beat(4)-1.57%
Max Revenue beat(4)2.66%
Revenue beat(8)6
Avg Revenue beat(8)1.15%
Revenue beat(12)8
Avg Revenue beat(12)0.91%
Revenue beat(16)8
Avg Revenue beat(16)-0.3%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0.25%
EPS NQ rev (3m)-7.56%
EPS NY rev (1m)0%
EPS NY rev (3m)-12.77%
Revenue NQ rev (1m)0.41%
Revenue NQ rev (3m)1.45%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.71%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.77 | ||
| Fwd PE | 1.54 | ||
| P/S | 0.25 | ||
| P/FCF | 2.27 | ||
| P/OCF | 1.66 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.2 |
EPS(TTM)5.38
EY56.45%
EPS(NY)6.19
Fwd EY64.96%
FCF(TTM)4.2
FCFY44.1%
OCF(TTM)5.73
OCFY60.16%
SpS37.53
BVpS-2.91
TBVpS-65.14
PEG (NY)0.35
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.36% | ||
| ROE | N/A | ||
| ROCE | 8.46% | ||
| ROIC | 6.09% | ||
| ROICexc | 6.6% | ||
| ROICexgc | 32.19% | ||
| OM | 19.13% | ||
| PM (TTM) | 0.99% | ||
| GM | 70.7% | ||
| FCFM | 11.2% |
ROA(3y)-1.07%
ROA(5y)-1.65%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.45%
ROIC(5y)4.93%
ROICexc(3y)5.7%
ROICexc(5y)5.13%
ROICexgc(3y)40.1%
ROICexgc(5y)34.22%
ROCE(3y)7.57%
ROCE(5y)6.85%
ROICexgc growth 3Y34.27%
ROICexgc growth 5Y-5.74%
ROICexc growth 3Y14.02%
ROICexc growth 5Y12.75%
OM growth 3Y1.02%
OM growth 5Y4.43%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.24%
GM growth 5Y-0.44%
F-Score7
Asset Turnover0.36
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 19.69 | ||
| Debt/EBITDA | 6.67 | ||
| Cap/Depr | 32.39% | ||
| Cap/Sales | 4.08% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 48.16% | ||
| Profit Quality | 1126.53% | ||
| Current Ratio | 1.31 | ||
| Quick Ratio | 0.98 | ||
| Altman-Z | 0.21 |
F-Score7
WACC6.77%
ROIC/WACC0.9
Cap/Depr(3y)22.53%
Cap/Depr(5y)20.55%
Cap/Sales(3y)3.31%
Cap/Sales(5y)3.43%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.33%
EPS 3Y-5.37%
EPS 5Y-2.91%
EPS Q2Q%2.65%
EPS Next Y5.02%
EPS Next 2Y7.99%
EPS Next 3Y11.04%
EPS Next 5Y-0.15%
Revenue 1Y (TTM)9.91%
Revenue growth 3Y4.5%
Revenue growth 5Y2.28%
Sales Q2Q%6.81%
Revenue Next Year5.61%
Revenue Next 2Y4.68%
Revenue Next 3Y3.21%
Revenue Next 5Y-0.19%
EBIT growth 1Y10.04%
EBIT growth 3Y5.56%
EBIT growth 5Y6.8%
EBIT Next Year12.61%
EBIT Next 3Y9.06%
EBIT Next 5Y-0.22%
FCF growth 1Y266.02%
FCF growth 3Y3.22%
FCF growth 5Y0.55%
OCF growth 1Y451.87%
OCF growth 3Y3.85%
OCF growth 5Y1.25%
BAUSCH HEALTH COS INC / BHC.CA FAQ
What is the ChartMill fundamental rating of BAUSCH HEALTH COS INC (BHC.CA) stock?
ChartMill assigns a fundamental rating of 4 / 10 to BHC.CA.
What is the valuation status for BHC stock?
ChartMill assigns a valuation rating of 9 / 10 to BAUSCH HEALTH COS INC (BHC.CA). This can be considered as Undervalued.
Can you provide the profitability details for BAUSCH HEALTH COS INC?
BAUSCH HEALTH COS INC (BHC.CA) has a profitability rating of 6 / 10.
Can you provide the financial health for BHC stock?
The financial health rating of BAUSCH HEALTH COS INC (BHC.CA) is 2 / 10.